SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Firefly Neuroscience, Inc. (AIFF) has a negative trailing P/E of -1.1, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -88.37%.
Criteria proven by this page:
- VALUE (0/100, Fail) — negative P/E indicates the company is currently operating at a loss — DCF and P/E-based valuation models cannot produce meaningful results for unprofitable companies (P/E -1.1); trailing earnings yield is below the 10-year Treasury yield (~4.3%), meaning bonds offer a better return (EY -88.37%).
- Trailing Earnings Yield -88.37% — negative yield confirms the company is currently unprofitable. Investors are paying for a turnaround rather than current earnings.
Overall SharesGrow Score: 29/100 with 0/7 criteria passed.
SharesGrow 7-Criteria Score
~
HEALTH
50/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — AIFF
Valuation Multiples
P/E (TTM)-1.1
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio2.95
P/S Ratio22.09
EV/EBITDA-1.1
Per Share Data
EPS (TTM)$-1.51
Book Value / Share$0.58
Revenue / Share$0.09
FCF / Share$-0.63
Yields & Fair Value
Earnings Yield-88.37%
Dividend Yield0.00%
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2020 |
828.2 |
0.00 |
212.20 |
24.62 |
- |
| 2021 |
-266.8 |
0.23 |
-387.77 |
36,522.88 |
- |
| 2022 |
-29.9 |
2.09 |
-53.69 |
0.00 |
- |
| 2023 |
-15.3 |
0.49 |
366.07 |
80.12 |
- |
| 2024 |
-1.7 |
0.00 |
-46.26 |
160.64 |
- |
| 2025 |
-0.6 |
-0.04 |
1.51 |
10.11 |
- |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2020 |
$0.05 |
$13.9M |
$413.38K |
3% |
| 2021 |
$-0.56 |
$32K |
$-4.38M |
-13690.6% |
| 2022 |
$-0.48 |
$0.00 |
$-3.79M |
- |
| 2023 |
$-0.33 |
$498K |
$-2.6M |
-522.7% |
| 2024 |
$-1.60 |
$108K |
$-10.46M |
-9685.2% |
| 2025 |
$-1.82 |
$1.14M |
$-19.88M |
-1741% |
